Polypeptide With Localisation/Targeting Motif TRIZ Cases

Engineered yeast cells express cannabinoid biosynthetic enzymes to produce cannabidiolic acid with high selectivity.

Activator peptides increase ADAM10 enzymatic activity to reduce beta-amyloid generation.

Modified gamma-glutamyl transferase hydrolyzes the construct to release cargo, avoiding toxicity from unstable peptide transport systems.

Antibodies target the NKp46 D2 domain to recruit natural killer cells without blocking ligand interactions, resolving receptor interference.

Intracellular DKK3b delivery avoids exogenous ER stress while blocking beta-catenin signaling and activating JNK pathways to induce apoptosis in tumor cells.

Adipose-derived exosomes deliver miRNA cargo via surface-attached targeting moieties.

Split DddA deaminase fragments reconstitute within mitochondria to install precise nucleotide changes, avoiding cellular toxicity from fully active proteins.

FcRn-binding polypeptides resolve low scalability in EV isolation by enabling pH-dependent affinity purification that extends circulation half-life.

An 18-amino acid Pichia pastoris signal sequence directs heterologous protein secretion without Kex2p cleavage dependency.

Body weight-based dosing standardizes fludarabine exposure to reduce relapse rates in leukemia patients undergoing adoptive cell therapy.

A fusion protein binds beta-2 microglobulin to form an MHC complex that engages inhibitory receptors on immune cells.

Modified FOXP3 polypeptides stabilize immunosuppressive effects while binding agents direct T-cells to specific tissues.

Recombinant beta-lactoglobulin proteins provide dairy-like heat stability and foaming in plant-based food formulations.

Optimized mRNA signal peptides with high hydrophobicity boost protein secretion up to six times, reducing therapeutic doses and side effects.

Phosphatidylserine-targeting CAR-T cells release granzyme B and perforin to lyse tumor cells that resist apoptosis.

Engineered NKT cells bypass graft-versus-host disease by removing T cell receptors, enabling safe off-the-shelf cancer immunotherapy.

Automated barcode and RFID tracking records custody events for biological samples, preventing misidentification delays in immunotherapy workflows.

Modified acid-alpha glucosidase variants using human alpha-1-antitrypsin signal peptides improve tissue distribution and reduce immunogenicity.

A rigid peptide linker connects transmembrane proteins to organelle signals, facilitating precise cellular trafficking.

Replacing native signal peptides with fibronectin leaders overcomes low secretion efficiency to boost recombinant polypeptide yield.

Allogeneic CAR T cells expand via optimized lymphodepletion regimens, preventing graft-versus-host disease and reducing toxicity.

Removing VPS39 from the HOPS complex inhibits late endosomal mTORC1 activation, resolving lysosomal dysfunction to improve CAR-T cell persistence.

Multivalent Clostridial toxins employ segmented binding domains to reduce dispersal side effects and immune responses while expanding therapeutic applications.

Artificial antigen-presenting cells replace costly paramagnetic beads by using heparin binding domains to concentrate viral vectors near activated T cells.

SSD guide protein fusion protects peptides from protease degradation, enabling scalable production with over 130 mg per gram yield.

Site-directed mutations in adenosine deaminase narrow the editing window to resolve the trade-off between high productivity and manufacturing precision.

Phage display libraries screen for ICK-like peptide motifs that improve binding affinity while reducing identification complexity.

An AAVhu68 capsid vector bypasses stem cell transplant limits by delivering GALC enzymes directly to neural tissue.

Segmented chimeric antigen receptors targeting glypican-3 resolve manufacturing complexity while enabling specific tumor inhibition.

Mutated RANKL ligands selectively inhibit osteoclast formation to treat bone loss diseases without triggering systemic immune complications.

Novel polypeptide degrades polyester plastics into reusable monomers, replacing energy-intensive mechanical recycling with cost-effective enzymatic hydrolysis.

Circular DNA donors with optimized backbone and homology arms increase editing frequency while reducing cell toxicity in human pluripotent stem cells.

Optimized antigen binding domains and chimeric antigen receptors target kallikrein related peptidase 2 to mediate potent T-cell cytotoxicity.

Specific chloroplast transit peptides direct dicamba monooxygenase to the correct cellular location.

A protease-conjugated nanoparticle degrades the extracellular matrix barrier, enabling deeper drug penetration into dense tumor tissues.

A coiled-coil spacer domain enables multimerization of chimeric antigen receptors through protein-protein interactions.

Phage lambda integrase enables precise site-specific DNA recombination, resolving genome engineering versatility and bacterial contamination trade-offs.

Hydrophilic QTY Fc fusion proteins intercept circulating cytokines to prevent receptor activation, reducing cytokine release syndrome severity in CAR-T therapy.

Human-origin dermcidin peptides deliver cargo without triggering immune responses or causing membrane damage.

Modified CAR T cells express specific molecules to overcome solid tumor microenvironment barriers, improving in vivo expansion.

An affinity-enhanced monomeric streptavidin chimeric antigen receptor binds tagged antibodies to enable precise tumor cell targeting.

Removing the B12D5 binding epitope from the GP64 protein eliminates neutralizing antibodies while maintaining high antigen immunogenicity.

Administering a recombinant GM-CSF antagonist reduces neuroinflammation and cytokine release syndrome in CAR-T cell therapy patients.

A cyclized peptide binds c-SRC to modulate gp130 activity and reduce pro-inflammatory gene expression.

Engineering CAR T cells with receptors for SIGLEC15 or kisspeptin targets solid tumors while sparing normal tissues.

Glycosylated fusion proteins shield ligands from protease cleavage during biogenesis, enabling robust surface display for targeted delivery.

Integrating 4-1BBL into B7-H3 chimeric antigen receptors overcomes limited antitumor activity in solid tumors by improving cell expansion and persistence.

Tet-On gene editing controls exogenous receptor expression in T cells, reducing graft versus host disease risk while avoiding exhaustion.

Replacing CD8 domains with CD28 sequences in GPC2-specific CARs enhances killing efficiency against neuroblastoma cells.

Engineering CAR-T cells with dual specificity against CDH17 and normal tissue markers resolves toxicity trade-offs in solid tumor immunotherapy.